LAVA Therapeutics N.V. Ordinary Shares (LVTX) Dividend History

LAVA Therapeutics N.V. is a biotech company focused on developing innovative immuno-oncology therapies. Specializing in gamma delta T cell engagers, LAVA aims to harness the immune system to target and destroy cancer cells. The company operates in the Netherlands and is dedicated to advancing treatments for various solid tumors.

Website:

Dividend History

LAVA Therapeutics N.V. Ordinary Shares currently does not pay dividends

Company News

  • LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

    LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that its CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference. The company is focused on developing its Gammabody platform of bispecific gamma delta T cell engagers for the treatment of solid tumors and hematologic malignancies.

    GlobeNewswire Inc.
    Featured Companies: MRK PFE
  • LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

    UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

    GlobeNewswire Inc.
  • LAVA Announces Annual Meeting of Shareholders

    UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST.

    GlobeNewswire Inc.
  • LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

    UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2024.

    GlobeNewswire Inc.
  • Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

    Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: ETON
Dividend data last updated 06/07/2025 20:28:37 UTC